(2R,3R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-fluoro-3-(2-fluorophenyl)butanoate | 1346145-55-8

分子结构分类

有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物

中文名称

——

中文别名

——

英文名称

(2R,3R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-fluoro-3-(2-fluorophenyl)butanoate

英文别名

ethyl (2R,3R)-3-(((R)-tert-butylsulfinyl)amino)-2-fluoro-3-(2-fluorophenyl)butanoate；ethyl (2R,3R)-3-[[(R)-tert-butylsulfinyl]amino]-2-fluoro-3-(2-fluorophenyl)butanoate

(2R,3R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-fluoro-3-(2-fluorophenyl)butanoate化学式

CAS

1346145-55-8

化学式

C₁₆H₂₃F₂NO₃S

mdl

——

分子量

347.426

InChiKey

POTDMDFAXMUOKF-IBRHDDFTSA-N

BEILSTEIN

——

EINECS

——

物化性质

沸点：

453.7±55.0 °C(Predicted)
密度：

1.210±0.06 g/cm3(Predicted)

计算性质

辛醇/水分配系数(LogP)：

3.2
重原子数：

23
可旋转键数：

8
环数：

1.0
sp3杂化的碳原子比例：

0.56
拓扑面积：

74.6
氢给体数：

1
氢受体数：

7

上下游信息

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	(R)-2-methylpropane-2-sulfinic acid [(1R,2R)-2-fluoro-1-(2-fluorophenyl)-3-hydroxy-1-methylpropyl]amide	1346145-59-2	C₁₄H₂₁F₂NO₂S	305.389
S(R)]-N-[(1R,2R)-2-氟-1-(2-氟苯基)-1-甲基-3-氧代丙基]-2-甲基-2-丙烷亚磺酰胺	(R)-N-((2R,3R)-3-fluoro-2-(2-fluorophenyl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide	1432511-83-5	C₁₄H₁₉F₂NO₂S	303.373
——	(R)-N-((2R,3R,4S)-3-fluoro-2-(2-fluorophenyl)-4,5-dihydroxypentan-2-yl)-2-methylpropane-2-sulfinamide	1606166-16-8	C₁₅H₂₃F₂NO₃S	335.415
——	(R)-2-methyl-N-((2R,3R,4S)-3,5,5,5-tetrafluoro-2-(2-fluorophenyl)-4-hydroxypentan-2-yl)propane-2-sulfinamide	1432511-87-9	C₁₅H₂₀F₅NO₂S	373.387
——	(R)-2-methyl-N-((2R,3R,4R)-3,5,5,5-tetrafluoro-2-(2-fluorophenyl)-4-hydroxypentan-2-yl)propane-2-sulfinamide	1432511-86-8	C₁₅H₂₀F₅NO₂S	373.387
——	(R)-N-((2R,3S)-3-fluoro-2-(2-fluorophenyl)pent-4-en-2-yl)-2-methylpropane-2-sulfinamide	1606166-15-7	C₁₅H₂₁F₂NOS	301.401
——	(5R,6R)-6-fluoro-5-(2-fluorophenyl)-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine	1346145-83-2	C₁₂H₁₄F₂N₂O	240.253
——	(5R,6R)-5-(5-amino-2-fluorophenyl)-6-fluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine	1346145-95-6	C₁₂H₁₅F₂N₃O	255.267
——	(4R,5R,6S)-5-fluoro-4-(2-fluorophenyl)-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-93-7	C₁₂H₁₁F₅N₂O	294.224
——	(4R,5R,6R)-5-fluoro-4-(2-fluorophenyl)-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-92-6	C₁₂H₁₁F₅N₂O	294.224
——	(4R,5R,6S)-5-fluoro-6-(fluoromethyl)-4-(2-fluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1606166-21-5	C₁₂H₁₃F₃N₂O	258.243
——	(5R,6R)-6-fluoro-5-(2-fluoro-5-nitro-phenyl)-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine	1346145-89-8	C₁₂H₁₃F₂N₃O₃	285.25
——	(4R,5R)-5-fluoro-4-(2-fluorophenyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1402413-11-9	C₁₁H₁₂F₂N₂O	226.226
——	(4R,5R,6R)-5-fluoro-4-(2-fluorophenyl)-6-(methoxymethyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1606165-68-7	C₁₃H₁₆F₂N₂O₂	270.279
——	(5R,6R)-5-{5-[((4-chloro-1-difluoromethyl-1H-pyrazol-3-yl)methyl)-amino]-2-fluoro-phenyl}-6-fluoro-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine	1400682-60-1	C₁₇H₁₈ClF₄N₅O	419.809
——	(4R,5R,6S)-4-(5-amino-2-fluorophenyl)-5-fluoro-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-99-3	C₁₂H₁₂F₅N₃O	309.239
——	(4R,5R,6R)-4-(5-amino-2-fluorophenyl)-5-fluoro-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-98-2	C₁₂H₁₂F₅N₃O	309.239
——	(4R,5R,6S)-5-fluoro-6-(fluoromethyl)-4-(2-fluoro-5-nitrophenyl)-4-methyl-5,6-dihydro-1,3-oxazin-2-amine	1606166-22-6	C₁₂H₁₂F₃N₃O₃	303.241
——	(5R,6R)-5-(5-(3-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ylamino)-2-fluorophenyl)-6-fluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine	1400682-58-7	C₂₀H₂₁ClF₂N₄O	406.863
——	N-(3-((4R,5R,6S)-2-amino-5-fluoro-6-(fluoromethyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide	1606164-56-0	C₁₉H₁₆F₃N₅O₂	403.364
——	(4R,5R,6S)-5-fluoro-4-(2-fluoro-5-nitrophenyl)-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-96-0	C₁₂H₁₀F₅N₃O₃	339.222
——	(4R,5R,6R)-5-fluoro-4-(2-fluoro-5-nitrophenyl)-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine	1432511-95-9	C₁₂H₁₀F₅N₃O₃	339.222
——	(4R,5R)-4-(5-amino-2-fluorophenyl)-5-fluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1402413-27-7	C₁₁H₁₃F₂N₃O	241.241
——	(2S,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol	1432511-90-4	C₁₁H₁₂F₅NO	269.214
——	(2R,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol	1432511-89-1	C₁₁H₁₂F₅NO	269.214
——	(4R,5R,6R)-N,N-bis(2,4-dimethoxybenzyl)-5-fluoro-4-(2-fluorophenyl)-6-(methoxymethyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1606165-67-6	C₃₁H₃₆F₂N₂O₆	570.633
——	(4R,5R)-5-fluoro-4-(2-fluoro-5-nitrophenyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine	1402413-21-1	C₁₁H₁₁F₂N₃O₃	271.223
——	N-(3-((4R,5R,6R)-2-amino-5-fluoro-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide	1432512-01-0	C₁₉H₁₄F₅N₅O₂	439.344
——	N-(3-((4R,5R,6S)-2-amino-5-fluoro-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide	1432512-02-1	C₁₉H₁₄F₅N₅O₂	439.344
——	5-cyano-pyridine-2-carboxylic acid [3-((4R,5R)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	1402412-33-2	C₁₈H₁₅F₂N₅O₂	371.346

反应信息

作为反应物：

描述：

(2R,3R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-fluoro-3-(2-fluorophenyl)butanoate 在盐酸、 lithium aluminium tetrahydride 、 potassium carbonate 、戴斯-马丁氧化剂作用下，以四氢呋喃、 1,4-二氧六环、甲醇、二氯甲烷、甲苯为溶剂，反应 6.17h，生成 (2R,3S)-3-fluoro-2-(2-fluorophenyl)pent-4-en-2-amine

参考文献：

名称：

[EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1

摘要：

本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物：其中X为-C(R3a)(R3b)-，-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-，R1为取代或未取代的烷基或类似物，R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。

公开号：

WO2014065434A1
作为产物：

描述：

2'-氟苯乙酮在 titanium(IV) tetraethanolate 、锌作用下，以四氢呋喃为溶剂，反应 10.25h，生成 (2R,3R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2-fluoro-3-(2-fluorophenyl)butanoate

参考文献：

名称：

[EN] 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS
[FR] COMPOSÉS DE 2,5,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-3-YLAMINE OU DE 2,3,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-5-YLAMINE

摘要：

这项发明涉及式(I)的化合物，其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。

公开号：

WO2011138293A1

点击查看最新优质反应信息

文献信息

[EN] 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2,3,4,5-TÉTRAHYDROPYRIDINE-6-AMINE

申请人：JANSSEN PHARMACEUTICA NV

公开号：WO2017050978A1

公开（公告）日：2017-03-30

The present invention relates to 2,3,4,5-tetrahydropyridin-6-amine compound inhibitors of beta-secretase having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, or dementia associated with beta-amyloid.

本发明涉及具有如公式(I)所示结构的β-分泌酶抑制剂2,3,4,5-四氢吡啶-6-胺化合物，其中基团如规范中所定义。该发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物和组合物预防和治疗涉及β-分泌酶的疾病，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆或与β-淀粉样蛋白相关的痴呆。
[EN] 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,5,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-3-YLAMINE OU DE 2,3,6,7-TÉTRAHYDRO-[1,4]OXAZÉPIN-5-YLAMINE

申请人：HOFFMANN LA ROCHE

公开号：WO2011138293A1

公开（公告）日：2011-11-10

This invention relates to compounds of the formula (I), wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

这项发明涉及式(I)的化合物，其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。
2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

申请人：Banner David

公开号：US20110312937A1

公开（公告）日：2011-12-22

This invention relates to compounds of the formula wherein A, B and R 1 to R 7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

这项发明涉及以下式的化合物其中A、B和R1至R7如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢紊乱疾病的药物。
1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

申请人：Gabellieri Emanuele

公开号：US20120238548A1

公开（公告）日：2012-09-20

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

本发明涉及具有BACE1和/或BACE2抑制活性的式I的1,4-噁唑啉，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。
[EN] 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS<br/>[FR] 1,4-OXAZÉPINES UTILISABLES EN TANT QU'INHIBITEURS DE BACE1 ET/OU BACE2

申请人：HOFFMANN LA ROCHE

公开号：WO2012126791A1

公开（公告）日：2012-09-27

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

本发明涉及具有BACE1和/或BACE2抑制活性的式I的1,4-噁唑啉，它们的制备，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。